KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT).

Joaquim Mullol, Joseph K Han, Tanya M Laidlaw, Claire Hopkins, Anju T Peters, Oliver Pfaar, Martin Desrosiers, Stella E Lee, Andrew P Lane, Claudia Chen, Yun Chon, Sandhia S Ponnarambil, Andrew Foster, Andrew W Lindsley, Christopher S Ambrose

Int Forum Allergy Rhinol 16(5) 484-494

PMID41493192
PMCIDPMC13147228
DOI10.1002/alr.70090
发表日期2026-01-06
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 7 张 PMC Figure,均未识别为 KM 图:FIGURE 1:图注未提示 KM 曲线;FIGURE 2:图注未提示 KM 曲线;FIGURE 3:图注未提示 KM 曲线;FIGURE 4:图注未提示 KM 曲线;FIGURE 5:森林图/亚组分析图;另有 2 张未列出。
摘要

摘要

BACKGROUND: Loss of smell is a principal symptom of chronic rhinosinusitis with nasal polyps (CRSwNP), affecting health-related quality of life and posing a safety hazard. METHODS: WAYPOINT (NCT04851964), a phase 3, multicenter trial in adults with uncontrolled CRSwNP, randomized patients 1:1 to receive tezepelumab 210 mg or placebo subcutaneously every 4 weeks for 52 weeks. Changes from baseline in biweekly mean Nasal Polyposis Symptom Diary (NPSD) loss of smell item, University of Pennsylvania Smell Identification Test (UPSIT), and 22-item Sino-Nasal Outcome Test (SNOT-22) loss of smell/taste item scores, as well as anosmia (UPSIT score ≤18) prevalence, were assessed over 52 weeks. RESULTS: Among 408 patients (tezepelumab [n = 203]; placebo [n = 205]), significant improvements with tezepelumab versus placebo in NPSD loss of smell item, UPSIT, and SNOT-22 loss of smell/taste item scores were seen at week 4 (least-squares mean [LSM] treatment difference [95% CI]: -0.36 [-0.46, -0.27]; 6.03 [4.72, 7.34]; and -1.01 [-1.22, -0.80], respectively) and week 52 (-1.01 [-1.18, -0.83]; 9.50 [7.84, 11.16]; and -1.90 [-2.20, -1.61]); all nominal p < 0.0001. Between-treatment differences in daily NPSD loss of smell item score were evident from day 7 (LSM treatment difference: -0.08 [95% CI: -0.15, -0.02]; nominal p < 0.01). Improvements in NPSD loss of smell, UPSIT, and SNOT-22 loss of smell/taste item scores were observed across multiple prespecified subgroups. Anosmia prevalence was lower with tezepelumab than placebo at week 4 (43.0% [n/N = 64/149] vs. 80.3% [n/N = 106/132]) and week 52 (31.5% [n/N = 47/149] vs. 75.8% [n/N = 100/132]). CONCLUSIONS: Tezepelumab provides early and sustained improvements in sense of smell among patients with uncontrolled CRSwNP.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(7,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Change from baseline in daily NPSD loss of smell item score over the first 28 days in the overall population. *Denotes nominal p < 0.05; **Denotes nominal p < 0.01. Error bars indicate 95% CIs. Higher scores indicate greater symptom severity (score range: 0–3). CI, confidence interval; LS, least‐squares; NPSD, Nasal Polyposis Symptom Diary.
非 KM Figure
FIGURE 2Change from baseline in UPSIT score over time in the overall population. **Denotes nominal p < 0.0001. Error bars indicate 95% CIs. Higher scores indicate lower symptom severity (score range: 0–40). a n represents the number of patients with observed data (tezepelumab and placebo, respectively): baseline, n = 197 and 204; week 4, n = 190 and 198; week 12, n = 185 and 192; week 24, n = 189 and 171; week 36, n = 188 and 154; week 52, n = 177 and 148. CI, confidence interval; LS, least‐squares; SD, standard deviation; UPSIT, University of Pennsylvania Smell Identification Test.
非 KM Figure
FIGURE 3Proportion of patients receiving (A) tezepelumab ( n = 149) and (B) placebo ( n = 132) in each UPSIT olfactory diagnosis category in the overall population over time (in patients with complete data at all time points). UPSIT, University of Pennsylvania Smell Identification Test.
非 KM Figure
FIGURE 4Change from baseline in SNOT‐22 loss of smell/taste item score over time in the overall population. **Denotes nominal p < 0.0001. Error bars indicate 95% CIs. Higher scores indicate greater symptom severity (score range: 0–5). CI, confidence interval; LS, least‐squares; SNOT‐22, 22‐item Sino‐Nasal Outcome Test.
非 KM Figure
FIGURE 5Change from baseline in NPSD loss of smell item score at week 4 and week 52 by subgroup. a Those without comorbid asthma or AERD/NSAID‐ERD. b Allergic rhinitis at screening was based on medical history as reported by the investigator. AERD, aspirin‐exacerbated respiratory disease; CI, confidence interval; LS, least‐squares; NP, nasal polyps; NPSD, Nasal Polyposis Symptom Diary; NSAID‐ERD, nonsteroidal anti‐inflammatory drug‐exacerbated respiratory disease.
非 KM Figure
FIGURE 6Change from baseline in UPSIT score at week 4 and week 52 by subgroup. a Those without comorbid asthma or AERD/NSAID‐ERD. b Allergic rhinitis at screening was based on medical history as reported by the investigator. AERD, aspirin‐exacerbated respiratory disease; CI, confidence interval; LS, least‐squares; NP, nasal polyps; NSAID‐ERD, nonsteroidal anti‐inflammatory drug‐exacerbated respiratory disease; UPSIT, University of Pennsylvania Smell Identification Test.
非 KM Figure
FIGURE 7Change from baseline in SNOT‐22 loss of smell/taste item score at week 4 and week 52 by subgroup. a Those without comorbid asthma or AERD/NSAID‐ERD. b Allergic rhinitis at screening was based on medical history as reported by the investigator. AERD, aspirin‐exacerbated respiratory disease; CI, confidence interval; LS, least‐squares; NP, nasal polyps; NSAID‐ERD, nonsteroidal anti‐inflammatory drug‐exacerbated respiratory disease; SNOT‐22, 22‐item Sino‐Nasal Outcome Test.
非 KM Figure